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Abstract
Background: The mortality in patients with persistent low CD4 count despite several years of HAART with
sustained viral suppression is poorly documented. We aimed to identify predictors for inadequate CD4 cell recovery
and estimate mortality in patients with low CD4 count but otherwise successful HAART.
Method: In a nationwide cohort of HIV patients we identified all individuals who started HAART before 1 January
2005 with CD4 cell count ≤ 200 cells/μL and experienced three years with sustained viral suppression. Patients
were categorized according to CD4 cell count after the three years suppressed period (≤ 200 cells/μL;
immunological non-responders (INRs), >200 cells/μL; immunological responders (IRs)). We used logistic regression
and Kaplan-Meier analysis to estimated risk factors and mortality for INRs compared to IRs.
Results: We identified 55 INRs and 236 IRs. In adjusted analysis age > 40 years and > one year from first CD4 cell
count ≤ 200 cells/μL to start of the virologically suppressed period were associated with increased risk of INR. INRs
had substantially higher mortality compared to IRs. The excess mortality was mainly seen in the INR group with >
one year of immunological suppression prior to viral suppression and injection drug users (IDUs).
Conclusion: Age and prolonged periods of immune deficiency prior to successful HAART are risk factors for
incomplete CD4 cell recovery. INRs have substantially increased long-term mortality mainly associated with
prolonged immunological suppression prior to viral suppression and IDU.
Background
The introduction of HAART has decreased morbidity
and mortality in HIV patients due to viral load (VL)
suppression and immunological recovery [1]. Still, the
immunological reconstitution after HAART initiation
varies depending on the pre-HAART level of immuno-
deficiency [2-7]. Several studies have shown that patients
with successful virological response to HAART and
incomplete initial CD4 recovery have increased mortality
[5,8,9]. However, the outcome is poorly documented for
patients with pesistent low CD4 count despite several
years of HAART with sustained VL suppression.
Within a nationwide cohort of HIV infected patients
we identified all individuals who were on stable
HAART, had been virally suppressed for more than
three years and had a CD4 cell count ≤ 200 cells/μL
prior to the virally suppressed period. In this population
we identified immunologic non-responders who did not
rise to a CD4 cell count > 200 cells/μLa f t e rt h et h r e e
years of sustained VL suppression. We aimed to identify
predictors for inadequate CD4 cell recovery and to
determine the mortality in the immunological non-
responders compared to those with an adequate CD4
cell response.
Methods
The study was performed as a nationwide cohort study.
In the first part of the study we estimated risk factors
for immunological non-response (CD4 cell count ≤ 200
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any medium, provided the original work is properly cited.cells/μL after three years of VL suppression). In the sec-
ond part of the study we estimated mortality in immu-
nological non-responders (INRs) versus immunological
responders (IRs).
Setting
Denmark had a population of 5.5 million as of 31
December 2008, with an estimated HIV prevalence of
approximately 0.07% in the adult population [10,11].
Patients with HIV infection are treated in one of the
country’s eight specialized medical centres, where they
are seen on an outpatient basis at intended intervals of
12 weeks. Antiretroviral treatment is provided free of
charge to all HIV-infected residents of Denmark. The
national criteria for initiating HAART have been
described previously [12].
Data sources
The Danish HIV Cohort study( D H C S ) ,d e s c r i b e di n
details elsewhere, is a population-based prospective
nationwide cohort study of all HIV-infected individuals
16 years or older at diagnosis and who are treated at
Danish HIV centres after 1 January 1995 [13]. December
31, 2008 the cohort included 5206 Danish residents.
Patients are consecutively enrolled, and multiple registra-
t i o n sa r ea v o i d e dt h r o u g ht h eu s eo fau n i q u e1 0 - d i g i t
civil registration number assigned to all individuals in
Denmark at birth or upon immigration. Data are updated
yearly and includes demographics, date of HIV infection,
AIDS defining events, date and cause of death and antire-
troviral treatment. CD4 cell counts and HIV-RNA mea-
surements are extracted electronically from laboratory
data files. After 1 January 2000 all viral load (VL) analy-
ses in Denmark were designed to measure VL below
50 copies/ml. Before that period lower limit of detection
were in some centres 199 copies/ml and 399 copies/ml
and these values are in the present study considered
being below 50 copies/ml. Patients are intended tested
yearly for hepatitis C antibodies, and if positive further
tested for hepatitis C RNA.
Primary causes of death were obtained from The
Danish Civil Registration System and The Danish Regis-
ter of Causes of Death [14]. Data on date of cancer diag-
nosis were obtained from The Danish Cancer Registry
and all patients diagnosed with cancer in the suppressed
period or 10 years previous to this were identified [15].
Study population
From DHCS we identified all HIV-1 positive patients,
who 1) started HAART before 1 January 2005, 2) had a
CD4 cell count ≤ 200 cells/μl at start of HAART, 3) had
a VL < 50 copies/ml for more than three consecutive
years before 1 January 2008, 4) had no intervals of more
than seven months between VL tests in the suppressed
period, and 5) had a CD4 cell count ≤ 200 cells/μla t
start of the virally suppressed period.
Patients were defined as IRs in case the first CD4 cell
count measured after 3 years of viral suppression was >
200 cells/μL and INRs in case the CD4 count was ≤ 200
cells/μL. Mortality was also stratified for more differen-
tiated CD4 cell strata after 3 years of viral suppression
(>200 cells/μLa n d≤ 350 cells/μL, > 350 cells/μLa n d≤
500 cells/μL and >500 cells/μL) but the prognosis dif-
fered little for all strata above 200 cells/μLw h yw e
chose to pool all CD4 responses above 200 cells/μLi n
one group (data not shown).
Statistics
Differences in characteristics between groups were eval-
uated by the c
2 test, Fisher’s exact test and Kruskal-
Wallis Test when appropriate.
We used binary logistic regression in order to identify
predictors for immunological non-response. The follow-
ing covariates were included in the model: Gender, age
at start of the suppressed period (≤ 40 years vs. > 40
years) (The cut point was based on the median age; IRs;
37.6 years (IQR; 32.1 - 45.3) and INRs; 42.6 years (IQR;
36.1 - 51.3)), race (Caucasian vs. non-Caucasian), route
of HIV infection (men who have sex with men (MSM)
vs. heterosexually vs. injection drug user (IDU) vs.
other), chronic HCV infection (positive vs. negative PCR
for HCV RNA), cancer prior to start of the suppressed
period, one or more AIDS defining event before start of
suppressed period, HIV diagnose before 1 January 1995,
nadir CD4 cell count < 50 cells/μL and > one year from
first CD4 ≤ 200 cells/μL to start of the virologically sup-
pressed period (The cut point of one year was based on
the median time from first CD4 cell count ≤ 200 to
start of the suppressed period; IRs; 0.7 year (IQR; 0.3 -
2.2) and INRs; 1.5 years (IQR; 0.4 - 3.2)). Selection of
potential confounders was performed using the “change
in estimate” method with age and gender forced into
the model [16].
Index date was defined as date of first CD4 cell count
measurement after three years of sustained viral suppres-
sion. We calculated person-years at risk from index date
until death, 1 January 2008, emigration or lost to follow-
up, whichever came first. We used Kaplan Meier analysis
to construct survival curves for INRs vs. IRs and further
stratified these by time from first CD4 measurement
≤ 200 cells/μL to start of the virologically suppressed per-
iod (≤ one year vs. > one year). Cox regression analyses
were used to estimate mortality rate ratios (MRR). We
further calculated MRRs stratified by cancer (no cancer
diagnosed prior to index date vs. cancer diagnosed prior
to index date), previous AIDS defining event (none vs. >
one or more AIDS defining events prior to index date)
and time from first CD4 measurement ≤ 200 cells/μLt o
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> one year). The estimates were adjusted for gender and
age.
In a robustness analysis we used a cut-off value of 500
copies/ml in the virologically suppressed period to test
the impact of VL cut-off on our estimates.
VL and CD4 cell response in the observation period
Using a previously described method [13] we grouped
all CD4 cell measurements and VL tests in the observa-
tion period in 12-weeks intervals and calculated the pro-
portion of CD4 measurements ≤ 200 cells/μLa n dV L
tests < 50 copies/ml for both IRs and INRs up to six
years after index date.
The study was approved by the Danish Data Protec-
tion Agency (Denmark has no Institutional review
boards). Data in the database is not publicly available.
SPSS statistical software, Version 15.0 (Norusis; SPSS
Inc., Chicago, Illinois, USA) and R software, version
2.8.1, was used for data analysis.
Results
In The Danish HIV Cohort Study 3165 patients started
HAART before 1 January 2005 (figure 1).291 study sub-
jects fulfilled the inclusion criteria and were followed for
1373 person-years during which 7 patients (2.4%) emi-
grated. 227 (78.0%) of the patients were males and 218
(74.9%) were Caucasians. Median time between VL tests
in the suppressed period was 88 days (IQR; 59 - 98).
After three years of sustained VL 236 (81.1%) patients
reached a CD4 cell count above 200 cells/μl( I R s )a n d
55 (18.9%) of the HIV infected patients did not (INRs).
Characteristics of IRs and INRs are shown in table 1.
In un-adjusted analysis age, Caucasian race and time
from first CD4 cell count ≤ 200 cells/μL to start of the
virologically suppressed period were associated with
immunological non-response (table 2). However, after
having adjusted for potential confounders only age and
time from first CD4 cell count ≤ 200 cells/μL to start of
the virologically suppressed period remained associated
with increased risk of being INR (table 2).
Figure 1 Study flow chart.
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Page 3 of 9The distribution of drug classes included in the last
HAART regimen prior to index date did not differ
between IRs and INRs (Additional file 1).
A total of 22 (7.6%) patients died in the observation
period, 11 (20.0%) in the INR group and 11 (4.7%) in
the IR group. As shown in figure 2, INRs had substan-
tially higher mortality compared to IRs. Unadjusted
MRR for INRs compared to IRs was 4.2 (95%CI; 1.8 -
9.6) and 3.4 (95%CI; 1.4 - 8.0) after adjustment for age
and gender. Figure 3 shows the mortality for IRs vs.
INRs stratified by time from first CD4 measurement ≤
200 cells/μL to start of of the virologically suppressed
p e r i o da n df r o mt h i sa n a l y s i si ti ss e e n ,t h a tt h em a i n
excess mortality was observed in the INRs with more
Table 1 Characteristics and demographics of immunological responders and non-responders
Characteristics Immunologic
responders
Immunologic non-
responders
P
N = 236 N = 55
Male gender 179 (75.8) 48 (87.3) 0.065
Age at time of index date, median (IQR), years 37.6 (32.1 - 45.3) 42.6 (36.1 - 51.3) <0.001
Caucasians 171 (72.5) 47 (85.5) 0.045
Route of HIV infection 0.059
Men who have sex with men 97 (41.1) 29 (52.7)
Heterosexually infected 98 (41.5) 14 (25.5)
Injection drug user 14 (5.9) 7 (12.7)
Other 26 (11.8) 3 (6.1)
Chronic HCV infection 20 (8.5) 8 (14.5) 0.169
Cancer within 13 years prior to index date 27 (11.4) 10 (18.2) 0.177
One or more AIDS defining events prior to index date 114 (48.3) 24 (43.6) 0.532
One or more AIDS defining events after index date 3 (1.3) 2 (3.6) 0.240
Diagnosed with HIV before 1 January 1995 94 (49.8) 27 (49.1) 0.210
Treated with zidofovir prior to index date 219 (92.8) 54 (98.2) 0.465
Nadir CD4 cell count, median (IQR), cells/μL 40 (10 - 82) 40 (15 - 57) 0.289
More than one year from first CD4 cell count ≤ 200 cells/μL to start of the virologically
suppressed period*
96 (40.7) 32 (58.2) 0.019
Time from start of HAART to start of the virologically suppressed period, median (IQR),
years
0.4 (0.2 - 1.1) 0.4 (0.3 - 1.3) 0.518
* Median time from first CD4 cell count ≤ 200 cells/μL to start of the virologically suppressed period was 0.7 year (IQR; 0.3 - 2.2) for IRs and 1.5 years (IQR; 0.4 -
3.2) for INRs.
Table 2 Odds ratios (OR) for immunological non-response in patients on successful HAART for more than three years
Characteristics OR Un-adjusted (95%
CI*)
OR, Adjusted ** (95%
CI)
Male gender 2.18 (0.94 - 5.09) 1.73 (0.73 - 4.14)
More than 40 years old at index date 2.53 (1.390 - 4.63) 2.32 (1.25 - 4.29)
Caucasians 2.23 (1.01 - 4.98) 1.09 (0.36 - 3.36)
Route of HIV infection
Men who have sex with men 1.0
Heterosexually infected 0.48 (0.24 - 0.96) 0.73 (0.30 - 1.78)
Injection drug user 1.67 (0.63 - 4.54) 3.06 (0.98 - 9.52)
Other 0.62 (0.22 - 1.75) 0.63 (0.20 - 1.96)
Chronic HCV infection 1.84 (0.76 - 4.43) 2.11 (0.79 - 5.61)
Cancer within 13 years prior to index date 1.72 (0.78 - 3.81) 1.47 (0.63 - 3.44)
One or more AIDS defining events prior to index date 0.83 (0.46 - 1.50) 0.84 (0.46 - 1.53)
Diagnosed with HIV before 1 January 1995 1.46 (0.81 - 2.63) 1.43 (0.72 - 2.86)
Nadir CD4 cell count less than 50 cells/μL 1.59 (0.86 - 2.96) 1.06 (0.43 - 1.75)
More than one year from first CD4 ≤ 200 cells/μL to start of the virologically suppressed
period
2.03 (1.12 - 3.68) 2.28 (1.18 - 4.43)
*Confidence interval (95%CI).
**All estimates adjusted for age and gender.
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virologically suppressed period. Of importance, the
excess mortality was observed up to 6.5 years after
initiation of virologically successful HAART. The INRs
did not experience substantially more AIDS defining
events in the observation period (3.6% vs. 1.3%).
128 patients (44.0%) had more than one year from
first CD4 measurement ≤ 200 cells/μL to start of the
virologically suppressed period. The un-adjusted MRR
among these 128 patients was 3.9 (95%CI; 1.5 - 10.6)
and after adjustment for age and gender it was 3.6 (95%
CI; 1.3 - 9.7). When excluding these patients from the
analysis the unadjusted MRR was reduced to 3.1 (95%
CI; 0.6 - 17.7) and after adjustment for age and gender
it was 1.8 (95%CI; 0.3 - 10.2). 90 (70.3%) of the 128
patients who had more than one year of immunological
suppression prior to the virologically suppressed period
were diagnosed before 1995. When excluding IDUs
from our analysis the unadjusted MRR was 2.5 (95%CI;
0.9 - 7.8) and the adjusted MRR was reduced to 1.8
(95%CI; 0.6 - 5.1). The un-adjusted MRR calculated
exclusively for IDUs was 12.7 (95%CI; 1.5 - 109.9) and
9.8 ((95%CI; 1.1 - 86.1) after adjustment for age and
gender. Exclusion of patients with previous cancer or
AIDS defining event, respectively, did not change the
estimates substantially. Only one death in each group
(one PML and one cryptococcal meningitis) appeared to
be a classical HIV related cause of death. Other causes
of death were: cancer (INR: 3, IR: 2), sudden death
(INR: 3, IR 3), liver related (INR:2, IR: 1), suicide (INR:
1 ,I R :1 ) ,o p i a t eo v e r d o s e( I N R :1 ,I R :0 ) ,p n e u m o n i a
(INR:2, IR:0) and cachexia (not HIV related) (INR: 0,
IR: 1).
80% of the INRs achieved a CD4 cell count > 200
cells/μL after six years of observation (i.e. more than
nine years after starting HAART). However, only 20
(35.1%) of the INRs were still under observation six
years after study inclusion. After six years of observa-
tion, 95.5% of the whole study population who were still
alive had fully suppressed VL.
Figure 2 Kaplan-Meier curves for overall survival according to immunologic response at index date: 1. CD4 cell count ≥ 200 cells/μL
(broken line), 2. CD4 cell count < 200 cells/μL (full line). Index date was defined at the date of first CD4 measurement after three years of viral
suppression (VL < 50 HIV-RNA copies/ml).
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suppression, 445 study subjects (372 IRs and 73 INRs)
were identified, of whom 18 (4.5%) patients in the IR
group and 15 in the INR group (20.5%) died during fol-
low-up. In the un-adjusted analysis age, Caucasian race,
IDU, time from first CD4 cell count ≤ 200 cells/μLt o
start of the virologically suppressed period and CD4 cell
count at start of the suppressed period were associated
with immunological non-response. However, after hav-
ing adjusted for potential confounders only age, IDU
and CD4 cell count at start of the suppressed period
remained associated with increased risk of being INR.
MRRs were 4.5 (95%CI; 2.3 - 9.0) and 3.69 (95%CI; 1.8 -
7.4) when adjusted for gender and age.
Discussion and Conclusions
In a population of HIV patients with initial low CD4
count we found that almost one out of five was INR
after three years of successful HAART. Older age and
more than one year of severe immune deficiency prior
to start of sustained VL were associated with INR. The
patients with insufficient immunological response had
substantially increased long term mortality. The
increased mortality was mainly seen in patients with
more than one year of immunological deficiency prior
to the period of sustained VL suppression and IDUs.
The major strength of this study is the identification of
a homogeneous group with stringent viral suppression,
essentially eliminating the possibility that incomplete VL
suppression explains our findings. The study had a
nationwide design with long and almost complete follow-
up including data on cancer as well as HCV status.
A limitation of the study is the small study population
(in part caused by the stringent definitions of INRs and
IRs) and the small number of outcomes, which did not
allow us to extend the logistic regressions analysis or to
calculate cause specific rate ratios of death. The study
population encompasses a highly selected group of
Figure 3 Kaplan-Meier curves for overall survival according to CD4 count at index date and stratified by time from first CD4 cell
count < 200 cells/μL to start of the virally suppressed period: 1) CD4 ≥ 200 cells/μL and ≤ one year (full line), 2) CD4 ≥ 200 cells/μL and >
one year (bar line). 3) CD4 < 200 cells/μL and ≤ one year (dot and bar line). 4) CD4 < 200 cells/μL and > one year (dot line).
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initial CD4 cell count, and a healthy survivor effect may
lead to underestimation of the excess mortality in the
INRs. Still, by using an extended virally suppressed per-
iod we allowed the patients to reach a steadier CD4 pla-
teau without the interference of CD4 cell redistribution
as seen after HAART start. HCV testing in the cohort is
“intended” and may only be performed yearly on known
high risk groups in the cohort e.g IDU why chronic
HCV may be underestimated in the cohort.
19% of the study patients did not have an adequate
immunological response to HAART. Our results corre-
sponds to the findings of other studies who found a
negative impact of low initial CD4 cell count on long-
term CD4 recovery [2,3,6,17-19].
INRs were significantly older than the IRs and age pre-
dicted inadequate CD4 cell recovery which corresponds to
the findings of several other studies [3,5,9,19,20]. In con-
trast to other studies, we did not find a statistically signifi-
cant association between IDU or chronic HCV infection
and INR [3,21]. However, when using a cut-off value of
500 copies/ml, IDU was associated with INR. This is prob-
ably due to the inclusion of a larger number of study
patients with these characteristics when allowing for viral
blips. Nadir CD4 cell count did not differ between the two
groups, presumably reflecting that immunological respon-
ders without a low nadir were able to escape above the
200 cells/μL threshold before full suppression was
observed. More INRs had more than one year from first
CD4 cell count ≤ 200 cells/μL to start of the virologically
suppressed period, indicating that they had a longer period
of immunological suppression than the IRs and this factor
was also associated with incomplete CD4 cell recovery.
Defect bone marrow function and decreased thymus activ-
ity are major suspects in delayed CD4 cell recovery in HIV
patients with severe immunodeficiency [4,22-25]. To our
knowledge no studies have been made on predictors for
bone marrow function in HIV infected patients, but our
results are in accordance with the findings of Dion et al,
who found that both older age and prolonged immunolo-
gical suppression were associated with decreased thymic
activity in virally suppressed HIV patients resulting in
slower CD4 recovery [26].
The excess mortality seen among the INRs was mainly
related to prolonged immunological suppression prior to
successful HAART and IDU. The median time from start
of HAART to start of the virologically suppressed period
was less than half a year. A longer period of immunologi-
cal suppression prior to the three years of sustained VL
suppression is therefore explained by delayed initiation of
HAART and not poor compliance. This is supported by
the fact that most of the patients with more than one
year of immunological suppression before start of the vir-
ologically suppressed period were diagnosed with HIV
before 1995 when treatment options were scarce. As
many of the INRs who died were patients who initiated
HAART in the mid-nineties it could be hypothesized
that resistance played a role, but the stringent design
with full VL suppression eliminates that possibility. We
find it unlikely that the late death of these patients were
directly related to the toxicity of the antiretroviral agents,
but cannot rule out that toxicity should interact with the
immune reconstitution. The increased mortality in
patients with delayed initiation of HAART is well docu-
mented [27] and the contribution of persistent immuno-
deficiency to the development of e.g. cancer has also
been observed by others [28]. It may be speculated that
intermittent viraemias in this setting would increase mor-
tality but the estimate remained unchanged in our sensi-
tivity analysis using a cut-off value of 500 copies/ml for
viral suppression, suggesting that either the impact of
low-level replication on death and immune reconstitu-
tion is limited or that the majority of bleeps below 500
remains laboratory artefacts.
We only encountered two AIDS related deaths sug-
gesting that these are rare after prolonged HAART even
without adequate CD4 recovery. Thus, it seems that the
INRs are not immune-suppressed in the classical sense
where a low CD4 count leads to AIDS defining diseases
and eventually death. Still, we cannot rule out that there
is a biological cause of the increased mortality in immu-
nological non-responders related to immunodeficiency
and that our study simply do not have power enough to
demonstrate an association.
The risk factors for incomplete CD4 cell recovery and
increased mortality points toward earlier diagnosis of HIV
as the main prophylactic measure. Also, the increased
mortality in these patients calls for increased concern in
terms of treatment and screening for co-morbidity.
We conclude that age and prolonged immunological
suppression are risk factors for incomplete CD4 cell
recovery in patients with otherwise successful HAART.
Patients with insufficient immunological response have
substantially increased long-term mortality compared to
IRs, but the increased mortality is mainly associated
with prolonged immunological suppression prior to VL
suppression and IDU. We therefore presume that in the
modern HAART era where patients are started early on
HAART the prevalence of insufficient CD4 recovery will
decrease substantially.
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